Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02586389 · ClinicalTrials.gov registry record
Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay
A clinical trial of Non-hematologic Cancer, sponsored by Sequenom.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT02586389: Recruiting study of Non-hematologic Cancer, sponsored by Sequenom.
NCT02586389 is a study of Non-hematologic Cancer that is actively recruiting participants, run by Sequenom. The registered enrollment target is 3,000 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02586389, a study of Non-hematologic Cancer, is actively recruiting participants, sponsored by Sequenom.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).
Primary Outcome
Analysis of circulating tumor DNA (ctDNA) in whole blood will be compared to baseline tumor DNA for concordance of mutations related to cancer.
Conditions Studied
Study Locations (1)
Idaho
- Idaho Urology - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2015-10-13 |
| Est. Completion | 2027-10-31 |
What NCT02586389 shows while recruiting
NCT02586389 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Non-hematologic Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02586389 reports a single indexed study location in Idaho.
Frequently Asked Questions
What is clinical trial NCT02586389 about?
NCT02586389 is a clinical study titled "Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay". This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).
What is the current status of trial NCT02586389?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2015-10-13. Estimated completion is 2027-10-31.
What conditions does trial NCT02586389 study?
This clinical trial studies the following conditions: Non-hematologic Cancer.
Who is sponsoring clinical trial NCT02586389?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02586389 being conducted?
This trial has 1 study location across Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI